David Nierengarten
Stock Analyst at Wedbush
(4.39)
# 361
Out of 5,106 analysts
211
Total ratings
52.91%
Success rate
18.26%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBOT BridgeBio Oncology Therapeutics | Reiterates: Outperform | $25 | $12.54 | +99.36% | 3 | Dec 11, 2025 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Outperform | $20 | $9.38 | +113.22% | 8 | Dec 8, 2025 | |
| ARGX argenx SE | Maintains: Outperform | $880 → $1,000 | $877.94 | +13.90% | 23 | Nov 14, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $9 → $7 | $9.02 | -22.39% | 11 | Nov 7, 2025 | |
| FATE Fate Therapeutics | Upgrades: Outperform | $5 → $7 | $1.15 | +508.70% | 16 | Oct 27, 2025 | |
| IRON Disc Medicine | Maintains: Outperform | $90 → $110 | $91.85 | +19.76% | 4 | Oct 17, 2025 | |
| ANAB AnaptysBio | Maintains: Outperform | $45 → $70 | $44.94 | +55.76% | 14 | Oct 15, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Outperform | $38 → $44 | $41.59 | +5.79% | 4 | Oct 13, 2025 | |
| NUVB Nuvation Bio | Reiterates: Outperform | $6 | $8.43 | -28.83% | 11 | Oct 13, 2025 | |
| NUVL Nuvalent | Reiterates: Outperform | $115 | $104.72 | +9.82% | 6 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $4 | $3.10 | +29.03% | 1 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $16.52 | +57.38% | 8 | Sep 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $22 | $9.03 | +143.63% | 3 | Aug 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $7 | $5.43 | +28.91% | 9 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $8 | $12.51 | -36.05% | 8 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $2.67 | +311.99% | 4 | Jun 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $27 | $13.33 | +102.63% | 8 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 | $19.57 | +68.63% | 6 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $80 → $20 | $9.83 | +103.46% | 7 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $18.48 | +67.75% | 2 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $87 → $90 | $77.08 | +16.76% | 3 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $47 | $46.87 | +0.28% | 7 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $30.17 | +32.58% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $33.62 | +33.85% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.01 | +890.10% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $3.30 | +445.45% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 | $42.11 | -76.25% | 3 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $4.10 | +192.68% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $27.36 | +108.33% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $50 → $175 | $28.35 | +517.28% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $3.54 | +14,024.29% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $6.95 | +763.31% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $7.55 | +151.66% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $36.23 | +107.01% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.17 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $4.39 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $10.36 | - | 3 | Nov 20, 2017 |
BridgeBio Oncology Therapeutics
Dec 11, 2025
Reiterates: Outperform
Price Target: $25
Current: $12.54
Upside: +99.36%
ORIC Pharmaceuticals
Dec 8, 2025
Reiterates: Outperform
Price Target: $20
Current: $9.38
Upside: +113.22%
argenx SE
Nov 14, 2025
Maintains: Outperform
Price Target: $880 → $1,000
Current: $877.94
Upside: +13.90%
Intellia Therapeutics
Nov 7, 2025
Maintains: Neutral
Price Target: $9 → $7
Current: $9.02
Upside: -22.39%
Fate Therapeutics
Oct 27, 2025
Upgrades: Outperform
Price Target: $5 → $7
Current: $1.15
Upside: +508.70%
Disc Medicine
Oct 17, 2025
Maintains: Outperform
Price Target: $90 → $110
Current: $91.85
Upside: +19.76%
AnaptysBio
Oct 15, 2025
Maintains: Outperform
Price Target: $45 → $70
Current: $44.94
Upside: +55.76%
Kiniksa Pharmaceuticals International,
Oct 13, 2025
Maintains: Outperform
Price Target: $38 → $44
Current: $41.59
Upside: +5.79%
Nuvation Bio
Oct 13, 2025
Reiterates: Outperform
Price Target: $6
Current: $8.43
Upside: -28.83%
Nuvalent
Sep 8, 2025
Reiterates: Outperform
Price Target: $115
Current: $104.72
Upside: +9.82%
Sep 8, 2025
Initiates: Outperform
Price Target: $4
Current: $3.10
Upside: +29.03%
Sep 2, 2025
Reiterates: Outperform
Price Target: $26
Current: $16.52
Upside: +57.38%
Aug 28, 2025
Reiterates: Outperform
Price Target: $22
Current: $9.03
Upside: +143.63%
Aug 13, 2025
Downgrades: Neutral
Price Target: $7
Current: $5.43
Upside: +28.91%
Jun 26, 2025
Reiterates: Neutral
Price Target: $8
Current: $12.51
Upside: -36.05%
Jun 23, 2025
Reiterates: Outperform
Price Target: $11
Current: $2.67
Upside: +311.99%
Apr 16, 2025
Maintains: Neutral
Price Target: $29 → $27
Current: $13.33
Upside: +102.63%
Mar 20, 2025
Reiterates: Outperform
Price Target: $33
Current: $19.57
Upside: +68.63%
Mar 14, 2025
Downgrades: Neutral
Price Target: $80 → $20
Current: $9.83
Upside: +103.46%
Feb 12, 2025
Reiterates: Outperform
Price Target: $31
Current: $18.48
Upside: +67.75%
Dec 2, 2024
Maintains: Outperform
Price Target: $87 → $90
Current: $77.08
Upside: +16.76%
Nov 25, 2024
Maintains: Outperform
Price Target: $40 → $47
Current: $46.87
Upside: +0.28%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $30.17
Upside: +32.58%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $33.62
Upside: +33.85%
Aug 13, 2024
Reiterates: Outperform
Price Target: $10
Current: $1.01
Upside: +890.10%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $3.30
Upside: +445.45%
May 24, 2024
Reiterates: Neutral
Price Target: $10
Current: $42.11
Upside: -76.25%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $4.10
Upside: +192.68%
Apr 23, 2024
Reiterates: Outperform
Price Target: $57
Current: $27.36
Upside: +108.33%
Feb 29, 2024
Upgrades: Outperform
Price Target: $50 → $175
Current: $28.35
Upside: +517.28%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $3.54
Upside: +14,024.29%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $6.95
Upside: +763.31%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $7.55
Upside: +151.66%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $36.23
Upside: +107.01%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.17
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $4.39
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $10.36
Upside: -